Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer | Zendy

AI Assistant Blog Pricing

Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.